Company registration number 12058346 (England and Wales)
EU MEDS DIRECT LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026
PAGES FOR FILING WITH REGISTRAR
EU MEDS DIRECT LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 6
EU MEDS DIRECT LIMITED
BALANCE SHEET
AS AT
31 MARCH 2026
31 March 2026
- 1 -
2026
2025
Notes
£
£
£
£
Fixed assets
Intangible assets
4
202,500
225,000
Tangible assets
5
3,075
3,809
205,575
228,809
Current assets
Debtors
6
3,821,581
4,718,708
Cash at bank and in hand
268,369
169,224
4,089,950
4,887,932
Creditors: amounts falling due within one year
7
(2,222,677)
(3,765,237)
Net current assets
1,867,273
1,122,695
Total assets less current liabilities
2,072,848
1,351,504
Provisions for liabilities
(51,393)
(57,202)
Net assets
2,021,455
1,294,302
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
2,021,355
1,294,202
Total equity
2,021,455
1,294,302
EU MEDS DIRECT LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 MARCH 2026
31 March 2026
- 2 -

For the financial year ended 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 3 June 2026 and are signed on its behalf by:
Mr Luke Pinnock
Director
Company registration number 12058346 (England and Wales)
EU MEDS DIRECT LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026
- 3 -
1
Accounting policies
Company information

EU Meds Direct Limited is a private company limited by shares incorporated in England and Wales. The registered office is Unit 3, Castlebridge Office Village, Castle Marina Road, Nottingham, NG71TN. The company registration number is 12058346.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Revenue

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

The nature, timing of satisfaction of performance obligations and significant payment terms of the company's major sources of revenue are as follows:

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that are recover able.

1.3
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Marketing platform
10% reducing balance
EU MEDS DIRECT LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026
1
Accounting policies
(Continued)
- 4 -
1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Computers
25% reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.6
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.7
Leases
As lessee

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the lease s asset are consumed.

EU MEDS DIRECT LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026
- 5 -
2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2026
2025
Number
Number
Total
4
6
4
Intangible fixed assets
Marketing platform
£
Cost
At 1 April 2025 and 31 March 2026
250,000
Amortisation and impairment
At 1 April 2025
25,000
Amortisation charged for the year
22,500
At 31 March 2026
47,500
Carrying amount
At 31 March 2026
202,500
At 31 March 2025
225,000
EU MEDS DIRECT LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026
- 6 -
5
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 April 2025
10,805
Additions
290
At 31 March 2026
11,095
Depreciation and impairment
At 1 April 2025
6,996
Depreciation charged in the year
1,024
At 31 March 2026
8,020
Carrying amount
At 31 March 2026
3,075
At 31 March 2025
3,809
6
Debtors
2026
2025
Amounts falling due within one year:
£
£
Other debtors
3,821,581
4,718,708
7
Creditors: amounts falling due within one year
2026
2025
£
£
Trade creditors
501,847
213,511
Corporation tax
113,433
246,145
Other taxation and social security
4,720
11,181
Other creditors
1,602,677
3,294,400
2,222,677
3,765,237
2026-03-31 2025-04-01 false false false 03 June 2026 CCH Software CCH Accounts Production 2026.100 No description of principal activity Mr John Soiza Mr Oliver Soar Mr Brett Soiza Mr Luke Pinnock 12058346 2025-04-01 2026-03-31 12058346 2026-03-31 12058346 2025-03-31 12058346 core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill 2026-03-31 12058346 core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill 2025-03-31 12058346 core:OtherPropertyPlantEquipment 2026-03-31 12058346 core:OtherPropertyPlantEquipment 2025-03-31 12058346 core:CurrentFinancialInstruments core:WithinOneYear 2026-03-31 12058346 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 12058346 core:CurrentFinancialInstruments 2026-03-31 12058346 core:CurrentFinancialInstruments 2025-03-31 12058346 core:ShareCapital 2026-03-31 12058346 core:ShareCapital 2025-03-31 12058346 core:RetainedEarningsAccumulatedLosses 2026-03-31 12058346 core:RetainedEarningsAccumulatedLosses 2025-03-31 12058346 bus:Director4 2025-04-01 2026-03-31 12058346 core:IntangibleAssetsOtherThanGoodwill 2025-04-01 2026-03-31 12058346 core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill 2025-04-01 2026-03-31 12058346 core:ComputerEquipment 2025-04-01 2026-03-31 12058346 2024-04-01 2025-03-31 12058346 core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill 2025-03-31 12058346 core:OtherPropertyPlantEquipment 2025-03-31 12058346 core:OtherPropertyPlantEquipment 2025-04-01 2026-03-31 12058346 bus:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 12058346 bus:SmallCompaniesRegimeForAccounts 2025-04-01 2026-03-31 12058346 bus:FRS102 2025-04-01 2026-03-31 12058346 bus:AuditExemptWithAccountantsReport 2025-04-01 2026-03-31 12058346 bus:Director1 2025-04-01 2026-03-31 12058346 bus:Director2 2025-04-01 2026-03-31 12058346 bus:Director3 2025-04-01 2026-03-31 12058346 bus:FullAccounts 2025-04-01 2026-03-31 xbrli:pure xbrli:shares iso4217:GBP